Almirall launches Constella in six European markets
This article was originally published in Scrip
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
You may also be interested in...
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.
Clovis Oncology has announced a public offering to raise $170m on the back of the company's huge share price rise following its presentation at the American Society of Clinical Oncology annual meeting in Chicago 3 June.